MedGenome seeks financial guidance from Argus Partners for a ~₹400 crore Series E investment round.
MedGenome Raises $47.5 Million in Series E Funding Round
MedGenome Inc., a leading genomic diagnostics and research services company, has successfully secured approximately ₹400 crore ($47.5 million) in a Series E fundraise. This significant investment will further strengthen MedGenome's efforts to reduce India's disease burden through early detection and targeted disease management using affordable, genetics-based diagnostic tools.
The co-leads for the fundraise were Maj Invest and existing investor Novo Holdings. Sofina Ventures also participated in the fundraise, demonstrating the confidence of multiple investors in MedGenome's mission and potential.
Argus Partners, a leading Indian law firm with expertise in corporate advisory, mergers and acquisitions, private equity, and banking, acted as the legal advisor for MedGenome in this funding round. The transaction team at Argus Partners included Partners, Senior Associates, and Associates, providing legal counsel related to the fundraising process, structuring, and compliance aspects of the transaction.
Anoushka Goel, Ishita Agarwal, Armaan Patkar, and Abhinav Bhalaik were among the members of the transaction team at MedGenome, contributing to the successful completion of the fundraise.
The funds raised will be used to broaden access to MedGenome's genomics and integrated diagnostics solutions across India and other emerging markets. This will enable more individuals to benefit from early and accurate disease detection, leading to improved health outcomes and reduced disease burden.
With this latest funding round, MedGenome continues to make strides in the field of genomic diagnostics and research, positioning itself as a key player in the global healthcare landscape.
- The funds raised from the Series E funding round will be allocated towards broadening investments in MedGenome's genomics and integrated diagnostics solutions, which would increase business operations in India and other emerging markets.
- MedGenome's strategic investments in genomic diagnostics and research, as a result of fundraising rounds like the recent Series E, are setting the company apart as a prominent player in the global finance landscape, particularly in the business sector of healthcare.
